This brand new textbook of rheumatoid arthritis (RA) is an important addition to the Oxford Textbooks in Rheumatology series, and provides a comprehensive overview of both the scientific and clinical aspects of the disease. Divided into eight sections - from the history, diagnosis, and epidemiology of the disease, through the pathogenesis, clinical presentation, and assessment to treatments and management strategies, both drug- and non-drug based - each chapter is written by leading clinicians and scientists in the field to deliver a contemporary view of RA. During the past two decades there have been revolutionary changes in the understanding and management of rheumatoid arthritis, in particular the development of biological treatments. This has had wide-ranging effects on almost all aspects of treatment, from effectiveness and intensity to the nature and the cost. Providing a comprehensive account of the modern ideas about the disease, the Oxford Textbook of Rheumatoid Arthritis is a key new addition to the literature, with each chapter providing a detailed background, key recent advances, and areas of doubt and future developments. Featuring over 170 photographs, radiological images, and clinical charts to aid both diagnosis and illustrate the rationale behind key scientific studies, this new title will prove an indispensable resource for specialist rheumatologists, trainees in rheumatology, and other members of the multi-disciplinary team.

Table of Contents:
1. History, diagnosis, and epidemiology 1: David L. Scott: The history of rheumatoid arthritis 2: Daniel Aletaha and Helga Radner: Diagnosis 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology of rheumatoid arthritis 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy 2. Pathogenesis 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley: Dysregulation of synovial fibroblasts in rheumatoid arthritis 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas: Dendritic cells and T cells in rheumatoid arthritis 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage destruction 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other mediators 3. Clinical presentation 11: Annette van der Helm-van Mil: Clinical features of rheumatoid arthritis 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg: Pre-rheumatoid arthritis 13: Katherine MacDonald, Jennifer Hannah, and James Galloway: Non-articular manifestations of rheumatoid arthritis 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid arthritis 4. Disease assessment 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis 16: Douglas Veale and Ursula Fearon: Synovial biopsies 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: Radiography in rheumatoid arthritis 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin: Ultrasound in rheumatoid arthritis 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in rheumatoid arthritis 5. Impact on life 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function in rheumatoid arthritis 21: Emma Dures and Neil Basu: Fatigue 22: David L. Scott and Allan Wailoo: Health economics 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway: Rheumatoid arthritis and work 6. Non-drug treatments 24: Lindsay Bearne and Christina Opava: Exercise 25: Heidi Siddle and Anthony Redmond: Foot health 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational therapy 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective 7. Drug treatments 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and José A. P. da Silva: Glucocorticoids 30: David L. Scott: Conventional disease modifying drugs 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in response to biologic agents 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK inhibitors in the treatment of rheumatoid arthritis 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler: Combination therapy in rheumatoid arthritis 38: Jeremy Sokolove: Translation of new therapies: from bench to bedside 39: James Galloway and Mark Yates: Adverse events in clinical studies in rheumatoid arthritis 8. Management and outcomes 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope: Prevention of rheumatoid arthritis 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and remission 42: David L. Scott: Clinical outcomes 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien: Clinical guidelines 44: Angela Zink and Anja Strangfeld: European biologics registers 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries